Table 8 Patient-level factors associated with receiving low-dose apixaban from the Veterans Health Administration, as compared to receiving full-dose, among those who met clinical criteria to receive full-dose apixaban for non-valvular atrial fibrillation. This table includes patients with only creatinine suggesting a need for low-dose therapy (i.e., age < 80, serum creatinine ≥1.5, and body mass > 60 kg, n = 2397)

 ≤ 69

31.6%

41.0%

REF

 70–74

24.6%

31.7%

1.01

(0.72, 1.39)

0.97

 75–79

43.8%

27.2%

2.09

(1.56, 2.81)

<  0.001

 Female

1.0%

0.5%

1.98

(0.42, 6.78)

0.32

 Male

99.0%

99.5%

REF

 White

78.6%

78.9%

REF

 Black

14.7%

15.3%

0.92

(0.64, 1.30)

0.64

 Other

6.7%

5.8%

1.11

(0.65, 1.81)

0.68

 Northeast

10.9%

11.4%

REF

 Midwest

17.3%

24.9%

0.69

(0.44, 1.11)

0.12

 West

18.8%

19.9%

0.83

(0.52, 1.33)

0.43

 South

53.0%

43.9%

1.15

(0.78, 1.75)

0.50

 61–69

13.1%

3.8%

3.76

(2.45, 5.70)

<  0.001

 70–79

12.1%

10.7%

1.18

(0.79, 1.72)

0.41

 80+

74.8%

85.4%

REF

 Heart Failure

34.8%

31.1%

1.12

(0.84, 1.47)

0.44

 Hypertension

86.3%

84.8%

1.13

(0.74, 1.75)

0.59

 Vascular Disease

31.0%

28.2%

1.16

(0.87, 1.53)

0.31

 Diabetes

70.9%

70.1%

0.96

(0.70, 1.32)

0.80

 Prior Bleeding

6.1%

4.7%

1.20

(0.69, 1.99)

0.50

 Stroke

11.2%

9.0%

1.09

(0.72, 1.62)

0.66

 1.50–1.59

13.7%

23.2%

REF

 1.60–1.79

23.6%

31.0%

1.33

(0.88, 2.02)

0.18

 ≥1.80

62.6%

45.8%

2.51

(1.76, 3.69)

<  0.001

 0–2

13.1%

12.3%

REF

 3–4

27.2%

32.8%

0.70

(0.44, 1.13)

0.14

 ≥ 5

55.0%

50.4%

0.82

(0.50, 1.38)

0.46